Summary Several reports have evaluated the correlation between cathepsin-D and overall survival or disease-free survival in node-negative breast cancer patients. Because conflicting data have so far been reported, a meta-analysis was conducted to clarify this problem. Eleven studies were included in our meta-analysis (total of 2690 patients). A specific meta-analytical methodology for censored data was used, and disease-free survival was the primary end point. Patients with low cathepsin-D levels had a significantly better disease-free survival than patients with high cathepsin-D values (meta-analytical odds ratio from 0.59 to 0.60 over the interval from 1 to 7 years). A secondary metaanalysis conducted exclusively on the data from eight studies based on cytosol assay gave substantially similar results. One limitation of our study is that the cut-off values to define high and low cathepsin-D concentrations were not identical in the various studies included in our meta-analysis (range from 20 to 78 pmol mg-' protein), thus introducing a possible bias in the statistical analysis of the data. However, a simulation based on the well-accepted method of the so-called publication bias showed that more than 100 null studies would be required to lead our results to a statistical level of non-significance. Considering the results of our meta-analysis, we conclude that the data presently available confirm a statistically significant association between high cathepsin-D values and poor disease-free survival in node-negative breast cancer patients.
The identification of new prognostic factors, more closely related to tumour cell biology, would be of utmost importance for treatment planning in human breast cancer. Improvement in discrimination between low-and high-risk cases is of major concern, particularly in the subset of node-negative patients, 70% of whom are cured by surgery alone and would therefore be spared the cost and potential toxicity of adjuvant chemotherapy (McGuire, 1989; Copper, 1991) . To date, several biological factors have been identified and proposed as potential prognostic indexes in human breast cancer. Among these, particular attention has been focused on proteolytic enzymes, such as cathepsin-D and urokinase-type plasminogen activator, which are involved in basement membrane/extracellular matrix degradation and tumour invasiveness and metastasis (Liotta et al, 1991) .
Cathepsin-D, firstly identified as a 52-kDa oestrogen-regulated glycoprotein (Westley et al, 1970) , displays both proteolytic activity in culture and an autocrine mitogenic activity in breast cancer cells (Vignon et al, 1986) . The involvement of cathepsin-D in cancer invasion is also supported by the demonstration that transfection of cathepsin-D cDNA into rat tumorigenic cells increases their metastatic potential in nude mice (Garcia et al, 1990 ). In addition, higher cathepsin-D levels have been found in breast cancer patients with metastatic lymph node involvement than in node-negative patients (Pujol et al, 1993; Winstanley et al, 1993; Gion et al, 1995) .
In recent years, great effort has been devoted to investigate the role of cathepsin-D as a possible marker of tumour invasiveness and poor prognosis, particularly in node-negative breast cancer patients. However, at present, the clinical usefulness of cathepsin-D measurement remains controversial; evidence has been reported that high cathepsin-D levels are associated with an unfavourable prognosis in node-negative breast cancer patients (Spyratos et al, 1989; Thorpe et al, 1989; Tandon et al, 1990; Kute et al, 1992; Isola et al, 1993) , but some authors failed to find any relationship between cathepsin-D and clinical outcome (Namer et al, 1991; Kandalaft et al, 1993; Janicke et al, 1993; Pujol et al, 1993) .
Inconsistency in the results may be due to variability of assay techniques, criteria of patient classification, different cut-off values of cathepsin-D assay and also to the low statistical power of individual studies that have often been conducted in relatively small patient series.
Meta-analysis provides an efficient tool for combining results of independent studies, thus increasing statistical power and possibly solving controversial issues.
In this report, we carried out a meta-analysis of the clinical studies evaluating the prognostic value of cathepsin-D in nodenegative breast cancer patients. (Stewart and Parmar, 1993) .
MATERIALS AND METHODS

Statistical techniques Survival meta-analysis
This statistical method [which has previously been used by Gregory et al (1992) , Messori et al (1994) and Berg et al (1994) ] was described originally by Peto (1987) (Messori and Rampazzo, 1993) , Version 4.38]. According to Messori and Rampazzo (1993) , the final result generated by the disease-free survival meta-analysis was denoted as 'log-rank odds-ratio' of meta-analysis.
Our primary meta-analysis of disease-free survival included the data of all clinical studies obtained from our literature search. Then, a secondary meta-analysis was conducted using exclusively the data of studies based on cytosol assays.
Other statistical calculations Extraction of raw survival data from the clinical studies
In order to carry out our survival meta-analysis, the survival curves published in the various clinical studies were analysed by the method of Fine et al (1993) . This method allows one to determine the distribution of the events and of the terminations of follow-up (i.e. cases of 'right-censored patients') stratified for each of the various time intervals of the follow-up. Controversial cases (in which this method provided time-specific survival rates, recomputed from raw data, that differed from the published actuarial curves) were solved by contacting the study's authors. The time intervals considered in this phase were the following: (1) from randomization to 12 months; (2) from 12 to 24 months; (3) from 24 to 36 months; (4) from 36 to 48 months; (5) from 48 to 60 months and (6) from 60 to 72 months. (1988) .
(1994) and by Ravdin et al (1994) , we obtained the disease-free survival data of node-negative patients directly from the authors Assessment of the inter-study heterogeneity There is a because these data were not explicitly reported in the published growing agreement about the need to perform a heterogeneity articles. The Appendix summarizes the characteristics of the assessment in all meta-analyses (Thompson, 1994) . The interstudies that were identified by our literature search but did not study heterogeneity was estimated using the equations reported in meet the inclusion criteria of the meta-analysis.
the appendix of Collins et al (1985) and in Section 2.2.2 of Messori and Rampazzo (1993) .
Meta-analysis including all studies
The results of our meta-analysis of disease-free survival are shown Publication bias calculations The issue of publication bias in Table 2 . The relative risk of relapse (expressed as odds ratios) (Simes, 1987) number m of negative (or null) studies required to lead a In our primary meta-analysis, the assessment of inter-study significant meta-analysis to non-significance. The value of m was heterogeneity gave a chi-square of 91.6 (d.f. = 11, P = 0.001) at 84 calculated by the formula described by Klein et al (1986 odds ratio at 60 months). Statistical significance' P = 0.01 P < 0.001 P < 0.001 P < 0.001 P < 0.001 P < 0.001 P < 0.001 aTo ensure the homogeneity of calculations, these study-specific rates were all recomputed from the survival data generated by the application of Fine's method (1993) . This recomputation was made using Equation 4b of Kaplan and Meier (1958 This assessment of publication bias tested the hypothesis of a greater likelihood of positive studies being published, but obviously could not check the stability of our results against the likelihood that the results of some studies might have been inflated by the use of an optimum cut-off point.
The data of Spyratos et al (1989) were introduced in our metaanalysis using the cut-off of 45 pmol mg-'. In a separate analysis (data not shown), we checked that the results of our meta-analysis remain virtually unchanged using the cut-off of 70 pmol mg-' reported by Spyratos et al (1989) .
Meta-analysis including cytosol-based studies
The eight papers by Pujol et al (1993) , Spyratos et al (1989) , Kute et al (1992) , Namer et al (1991) , Janicke et al (1993) , Tandon et al (1990) , Seshadri et al (1994) and Ravdin et al (1994) (Table 1) were included in this secondary meta-analysis focused on studies using cytosol assays. The results were very similar to those produced by the first meta-analysis. Statistical significance was slightly less marked (value at 24 months: z = 3.96, P < 0.001; value at 48 months: z = 4.36, P < 0.001; value at 72 months: z = 4.61, P < 0.001); the values of odds ratios at the various times were all around 0.60 (value at 24 months: 0.56 with 95% CI of 0.42-0.75; value at 48 months: 0.62 with 95% CI of 0.50-0.77; value at 72 months: 0.63 with 95% CI of 0.52-0.77). Interestingly enough, the level of inter-study heterogeneity showed no decrease after the exclusion of studies using immunohistochemical techniques.
DISCUSSION
To our knowledge, this is the first study in which the possible prognostic role of a biological factor has been evaluated by means of a meta-analytical approach based on survival methodology. One advantage of the meta-analytical approach is that it enables the circumvention of the lack of statistical power as a result of the relatively small sample size of many studies. The choice to carry out this meta-analysis on the prognostic role of cathepsin-D in nodenegative breast cancer patients stems from the following reasons: (1) evidence has been reported about the direct relationship of cathepsin-D with tumour cell invasiveness and metastatic behaviour (Garcia et al, 1990; Pujol et al, 1993; Winstanley et al, 1993; Gion et al, 1995) ; (2) cathepsin-D has been included among the biological factors potentially useful for discrimination between high-and lowrisk patients to avoid adjuvant overtreatment in the latter group (Bevilacqua et al, 1994) ; (3) although the negative prognostic role of high cathepsin-D levels in node-negative breast cancer patients has been demonstrated by several authors (Spyratos et al, 1989; Thorpe et al, 1989; Tandon et al, 1990; Kute et al, 1992; Isola et al, 1993) , conflicting results have also been reported (Namer et al, 1991; Kandalaft et al, 1993; Janicke et al, 1993; Pujol et al, 1993) . Our study demonstrated that elevated cathepsin-D values identify nodenegative breast cancer patients characterized by unfavourable prognosis in terms of disease-free survival. Although heterogeneity of the studies as well as different definitions of cathepsin-D positivity might have been a source of bias, the exclusion of studies analysing cathepsin-D content by immunohistochemistry did not change the statistical significance of our meta-analytical results. Moreover, despite a certain degree of heterogeneity in the percentage of cathepsin-D positivity, our publication bias simulations demonstrated that more than 100 null studies would be required to reverse our results to the level of statistical non-significance.
It should be noted that several reports could not be included in our meta-analysis because of the incomplete presentation of survival curves. This fact emphasizes the need for studies dealing with the assessment of potentially prognostic biological factors to ensure a sufficient level of reporting of the results to allow reappraisal in meta-analysis studies.
It has been suggested that the relationship of total tumour cytosolic cathepsin-D to adverse prognosis may be impaired by the presence of cathepsin-D in non-epithelial cells. In particular, it has been found that stromal and macrophage-like cells are cathepsin-D positively immunostained in approximately 35% of cases defined as negative according to tumour cell immunoreactions irrespective of the use of monoclonal (Isola et al, 1993) or polyclonal (Domagala et al, 1992) antibodies. However, Roger et al (1994) reported that cytosolic cathepsin-D levels correlated with cathepsin-D expression in cancer cells, and several studies agree with the finding that cathepsin-D contents in stromal and cancer cells are directly correlated (Isola et al, 1993; Eng Tan et al, 1994; Ravdin et al, 1994) .
On the other hand, results obtained by immunohistochemistry showed the highest degree of heterogeneity, probably because of differences in the antibodies used and in cathepsin D positivity criteria (see Table 2 ); some studies demonstrated the adverse prognostic role of tumour cell cathepsin-D content (Isola et al, 1993; Winstanley et al, 1993; Roger et al, 1994) , while others failed to find any relationship between tumour cell cathepsin-D expression and clinical outcome (Domagala et al, 1992; Kandalaft et al, 1993; Armas et al, 1994) and only one ) showed a favourable impact of tumour cell cathepsin-D on prognosis. Ravdin et al (1994) suggested that cathepsin-D assessment by Western blot should not be routinely used for the prognostic characterization of breast cancer patients.
Although a general consensus on the routine use of this technique is still far from being achieved, the assessment of cathepsin-D content by means of immunoradiometric assay seems to be likely to give more reliable and comparable inter-study results as assessed by the EORTC Receptor Study Group (Benraad et al, 1992) .
One limitation of our study is that the cut-off values that differentiate between high and low cathepsin-D concentrations were not identical in the various studies but varied from 20 to 78 pmol mg-' protein. While this fact could have introduced a bias increasing the statistical significance of our results, the high number of null studies required in our publication bias assessment to reverse our results to non-significance supports the conclusion of our analysis.
We cannot rule out the possibility that some of the studies included in our analysis might have been influenced by the selection of an optimum cut-off point, but the overall evidence emerging from our study seems to be sufficient to support the conclusion that cathepsin-D has a prognostic role in these patients.
In their paper that suggested a poor correlation between prognosis and cathepsin-D levels, Ravdin et al (1994) conducted an exploratory analysis on different cathepsin-D cut-off values wherein these cut-off values were retrospectively varied over the range from 1 to 1000 units. This analysis showed that the 'optimum' cut-off value (i.e. the value of Cathepsin-D that produced the highest statistical correlation with a P-value of 0.009) was around 22 units. Furthermore, Ravdin et al (1994) tried to ascertain to what extent this retrospective identification of the optimum cut-off could have contributed to an artifactual P-value *An analytical printout of the survival data of the clinical studies included in our meta-analysis is avallable from the authors upon request.
(i.e. to an overestimation of the statistical significance of the correlation between cathepsin-D levels and prognosis) and to what extent their findings, which revealed this apparent correlation using the retrospective cut-off of 22 units, could be compatible with a purely casual result (i.e. a result derived from a simulated population wherein the correlation was totally absent). This latter analysis of Ravdin et al (1994) , which was based on the simulation of about 300 different data sets, showed that there was a one in six chance that the high correlation found in the primary analysis was purely casual. The authors therefore concluded that their hypothesis of a 'true' correlation was not supported by sufficient evidence and that the apparent cut-off point found retrospectively in their real data set was likely to be casual.
While these conclusions proposed by Ravdin et al (1994) , after analysis of their data, are perhaps too conservative, it should be stressed that the findings reported by these authors are however consistent with a correlation at P-levels of about 0.10 or 0.20 and therefore suggest at least the presence of a statistical trend.
To better interpret the results of our meta-analysis, we tried to plan a simulation based on the comparison of a hypothetical population with no correlation vs our real patient population. Unfortunately, the lack of individual patient data on cathepsin D assays did not allow us to produce reliable statistical results on this point.
Another controversial point regards the methodology of the survival meta-analysis used in our study. Because there is presently no consensus on which methodology should be recommended for survival meta-analysis, we analysed all survival data included in our study using a different method of survival metaanalysis (Simes, 1987) in which median survival is used for comparing two patient groups with one another across a series of different clinical studies. This further analysis (data not shown) produced essentially the same results obtained by our primary survival meta-analysis.
Therefore considering the results of our primary meta-analysis (together with the relatively low inter-study difference in the cutoff values and the results of our publication bias assessments), we conclude that the data presently available confirm a statistically significant association between cathepsin-D and disease-free survival in breast cancer.
